CClinicalTrials.gg
Not yet recruitingNCT07401251LEIPUpdated Sep 30, 2026

Lead Exposure Intervention Program

An interventional study of Home visit with tailored messages and In-clinic lead risk reduction intervention in Lead Exposure and High Blood Lead Level, sponsored by University of Washington. Not yet recruiting at 1 site in Kenya. Open to participants aged 12 Months to 72 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Washington · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
12 Months to 72 Months
Sex
All
01

Study summary

The goal of this clinical trial is to learn if BLL (blood lead level) screening and "healthy home" lead prevention program created in the US is adaptable to a Sub-Saharan African context. It will also work to address child lead exposure in Nairobi, Kenya. The main questions it aims to answer is:

  • Can materials and protocols developed for a US audience be effective in a Sub-Saharan African one?
  • Is there a difference in learning and action between groups that receive different degrees of intervention?

Researchers will compare the outcomes of a group that received lead risk reduction information only in the clinical setting to a group that also received a home visit and tailored risk reduction messages.

Participants will:

  • Have their child's blood lead levels measured at several timepoints
  • Take part in a questionnaire about lead risk
  • Receive lead risk reduction messaging either only in the clinic setting or also in their homes
  • Have their knowledge and risk reduction behaviors measured
02

Conditions studied

  • Lead Exposure
  • High Blood Lead Level

Keywords

  • lead
  • pediatric
  • Sub-Saharan Africa
  • lead risk reduction
03

Who can participate

Ages eligible
12 Months to 72 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Child age 12-72 months
  • Parent or primary caregiver that is a biological relative is available to give informed consent for LEIP study
  • Parent/caregiver is 18 years of age or older or is an emancipated minor
  • Parent available for 9 months follow-up

Exclusion criteria

Exclusion Criteria:

-Parent unwilling to be contacted for the purposes of tracing and follow-up

04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    Immediate messages

    Caregivers of children with elevated blood lead levels will be provided with immediate messages about lead risk mitigation in the clinic setting. They will receive follow-up at 3 months and 9 months and will complete recall, behavior, and recheck questionnaires and their children will have BLL rechecks.

    Behavioral: In-clinic lead risk reduction intervention

  • Experimental
    Home visit

    Caregivers of children with elevated blood lead levels will be provided with immediate messages about lead risk mitigation in the clinic setting. They will also receive a home observation visit and have those risk reduction methods reiterated and tailored to their home situation. They will receive follow-up at 3 months and 9 months and will complete recall, behavior, and recheck questionnaires and their children will have BLL rechecks.

    Behavioral: Home visit with tailored messages · Behavioral: In-clinic lead risk reduction intervention

Interventions

  • BehavioralHome visit with tailored messages

    The home visit will be conducted within 2 weeks of initial screening. During the home visit, the lead exposure risk survey will be re-administered, for comparison to in-clinic self-report survey responses. In addition, an observational checklist of potential lead exposure risk factors will be conducted to identify and discuss residential features and items in the home environment that may be influencing their BLL. Tailored messages on lead exposure risk reduction will be provided. A random sample of caregivers will complete an in-depth interview to gather barriers, understandability, and acceptability of the lead risk reduction messages received.

  • BehavioralIn-clinic lead risk reduction intervention

    For children with BLL \< 5 ug/dL, the result will be provided to the caregiver, together with standard post-test messaging on reducing lead exposure. A job-aid, such as a poster, showing common sources of lead exposure in children, and important sources of iron rich foods will be used to guide messaging. For BLLs ≥ 5, tailored messaging on potential sources identified on the risk factor survey will be provided. A random sample of caregivers will complete an in-depth interview to gather barriers, understandability, and acceptability of the lead risk reduction messages received.

05

What researchers measure

Primary outcomes

  1. Recall of survey risk factors

    Lead risk surveys will be completed by participants during the clinic visit and at 3 and 9 months post home visit. Qualitative analysis of the lead risk survey will summarize themes on understandability and acceptability of survey items and messages. The rapid analysis will also explore facilitators and barriers to uptake of recommended exposure reduction measures, and individual level determinants associated with uptake (e.g., empowerment, self-efficacy).

    Time frame: 3 and 9 months post clinic visit

  2. Self report of risk-reduction behavior

    Assess the proportion of caregivers self-reporting uptake of at least one of their risk reduction recommendations within arms and by BLL.

    Time frame: 3 and 9 months post clinic visit

Secondary outcomes

  1. Differences in outcomes between arms

    Using risk survey responses and self-reported changes in risk reduction behavior, we will compare the participants of both arms to assess for differences.

    Time frame: 3 and 9 months post clinic visit

Other outcomes

  1. Uptake of the BLL re-check

    Return for a re-check visit is an indicator of caregiver awareness of importance of reducing lead exposure. We will summarize the proportions of caregivers returning for each BLL re-check visit for each arm.

    Time frame: 3 and 9 months post-initial visit

  2. Change in BLL

    Change in BLL at re-checks. We do not anticipate observing a significant reduction in child BLL, given that caregivers might not have the ability to identify and/or modify a lead risk exposure.

    Time frame: 3 and 9 months post-initial clinic visit

06

Study locations

1 site
  • Dandora and Baba Ndogo Health Centres
    Nairobi, Kenya
07

References and documents

Publications

  • Onoh I, Mugo C, Riederer A, Maleche-Obimbo E, Were FH, Loftus C, Mukumbang F, Lumumba E, Richardson B, Edemba PW, Mutai BC, Karr C, Benki-Nugent S. Adapting, piloting, and evaluating a pediatric lead screening and risk-reduction intervention in Nairobi: A hybrid implementation-effectiveness trial protocol. PLoS One. 2026 Jun 4;21(6):e0349153. doi: 10.1371/journal.pone.0349153. eCollection 2026. PubMed 42241430 ↗
  • Onoh I, Mugo C, Riederer A, Maleche-Obimbo E, Were FH, Loftus C, Mukumbang F, Lumumba E, Richardson B, Edemba PW, Mutai BC, Karr C, Benki-Nugent S. Adapting, piloting, and evaluating a pediatric lead screening and risk-reduction intervention in Nairobi: A hybrid implementation-effectiveness trial protocol. medRxiv [Preprint]. 2026 Apr 30:2026.04.28.26351918. doi: 10.64898/2026.04.28.26351918. PubMed 42094172 ↗

Individual participant data

Plan to share: Yes — All data other than patient direct or indirect identifiers will be shared.

08

Registry details

Key details

Study ID
NCT07401251
Lead sponsor
University of Washington
Collaborators
National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)
Responsible party
Sarah Benki-Nugent (Associate Professor, Department of Global Health, University of Washington) — Principal investigator
First posted
Feb 10, 2026
Start date
Jan 2027 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Karen Jansen
Contact
kjansen@uw.edu
206-685-6392
Sarah Benki-Nugent
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion